



ASX & Media Release

Patrys Granted US Patent for Lead Product PAT-LM1

- Second granted US patent for lead product PAT-LM1 offers protection through to March 2024
- Patent covers the PAT-LM1 antibody and binding fragments

Melbourne, Australia; 8 November, 2013: Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company is pleased to advise that it has been granted a second US patent for lead anti-cancer product PAT-LM1.

The United States Patent Office has issued the official “Letters Patent” on a key patent in the PAT-LM1 family; US patent 8,562,995 entitled “Neoplasm specific antibodies and uses thereof”. This is the second patent to be granted in the US jurisdiction, and the third for the PAT-LM1 family. In June this year a patent covering the use of the PAT-LM1 antibody or binding fragments for the treatment or prevention of metastasis was granted in New Zealand.

The patent claims the PAT-LM1 antibody and other variants comprising the Complementary Determining Region (CDRs) of the PAT-LM1 antibody.

“This patent expands our intellectual property position and protects our lead product PAT-LM1. The US is a major strategic jurisdiction for therapeutic antibodies. The granting of three patents in the PAT-LM1 family further increases the value of Patrys’ patent assets, especially in the field of oncology”, said Dr. Marie Roskrow, Patrys’ Chief Executive Officer.

Patrys has related patents pending both internationally and in the United States.

PAT-LM1 is currently under preclinical development.

-Ends-

For further information, please contact:

Patrys Limited:
Dr. Marie Roskrow
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
rwilson@buchanwe.com.au

Patrys Media:
Kellie Hanrick
Buchan Consulting
P: +61 3 9866 4722
khanrick@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com